Clinical utility of the carcinoembryonic antigen level in patients with stage III colon cancer after surgery and adjuvant chemotherapy
Shohei Udagawa(Japanese Foundation For Cancer Research), Eiji Shinozaki(Japanese Foundation For Cancer Research), Ryotaro Kozuki(Japanese Foundation For Cancer Research), Toshiki Mukai(Japanese Foundation For Cancer Research), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Nozomi Kurihara(Japanese Foundation For Cancer Research), Hiroki Osumi(The Cancer Institute Hospital), Takeru Wakatsuki, Yosuke Fukunaga(Japanese Foundation For Cancer Research), Akira Ooki(Japanese Foundation For Cancer Research), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Takashi Akiyoshi(The Japanese Society of Gastroenterological Surgery)
Cited by 3
Related Papers
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2021|411
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
|Cancer Science|2014|238